Fundraising FoxAmaryllis Therapeutics, Inc. Healthcare USA
Cambridge, US · Founded 2024 · 1 known investors
Find your way into Amaryllis Therapeutics, Inc. Healthcare USA
Sign up to find every way you can get introduced to Amaryllis Therapeutics, Inc. Healthcare USA
- Your email: who you already know at Amaryllis Therapeutics, Inc. Healthcare USA, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amaryllis Therapeutics, Inc. Healthcare USA team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
Founders & leadership
JK
Jeongseuk KangExecutive
Board
EK
Emmanouil KaragiannisBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 round · 2024
▶$1.5MraisedSep 2024 · 1 investors · OtherRule 506(b)
▶$1.5MraisedSep 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jeongseuk KangExecutive Officer, Director
- Emmanouil KaragiannisDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Amaryllis Therapeutics, Inc. Healthcare USA do?
- Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening. Its lead peptide enables subcutaneously injected payloads such as antibodies, mRNA, ASO, and siRNA to cross the blood-brain barrier, initially targeting the brain.
- Who are Amaryllis Therapeutics, Inc. Healthcare USA's investors?
- Amaryllis Therapeutics, Inc. Healthcare USA's investors include ACVC Partners.
- How much funding has Amaryllis Therapeutics, Inc. Healthcare USA raised?
- Amaryllis Therapeutics, Inc. Healthcare USA has disclosed $1.5M raised across 1 round.
- Where is Amaryllis Therapeutics, Inc. Healthcare USA headquartered?
- Amaryllis Therapeutics, Inc. Healthcare USA is headquartered in Cambridge, US.